Home Innovation Medical Technology AlloStem shows promise in redu...

AlloStem shows promise in reducing insulin dependency for T2D

Medical Technology

Business Honor
11 Febuary, 2025

AlloStem shows promising results in reducing insulin dependency for type 2 diabetes, exploring other treatments.

Creative Medical Technology’s investigational allogenic cell line, AlloStem (CELZ-201), has shown encouraging results in reducing insulin dependency in patients with type 2 diabetes (T2D). In a pilot study with 20 participants, 10 received AlloStem treatment, while the remaining participants were given optimized medical therapy. After one year, AlloStem achieved an 80% efficacy rate in lowering insulin dependency and stabilizing hemoglobin A1c levels. Notably, no serious safety events were reported, highlighting AlloStem's potential as a viable treatment option for late-stage T2D. This success has motivated Creative Medical Technology to advance AlloStem's development for T2D and investigate its use for other medical conditions.

The company’s CEO, Timothy Warbington, expressed enthusiasm about the findings, describing them as a significant milestone in transforming diabetes treatment. AlloStem is part of a diverse portfolio focused on enhancing therapies for both type 1 and type 2 diabetes, which includes CELZ-201 for early-stage type 1 diabetes (T1D) and CELZ-101 for brittle T1D.

AlloStem is currently in a Phase 1/2a trial (CREATE-1) for newly diagnosed T1D patients at the University of Miami’s Diabetes Research Institute. This trial, which has received approval from the FDA and an institutional review board (IRB), aims to evaluate the safety and efficacy of CELZ-201 when administered through intra-arterial infusion.

Beyond diabetes, Creative Medical Technology is exploring AlloStem’s potential in treating chronic lower back pain. A Phase 1/2a ADAPT clinical trial is planned to assess AlloStem’s StemSpine procedure for alleviating pain related to degenerative disc disease. This trial, which received IRB approval in October 2023, aims to provide a non-surgical alternative for millions suffering from chronic back pain, a condition that poses significant economic and health challenges.